(Q35062598)

6 August 2017

1 reference

title

The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease (English)

1 reference

6 August 2017

1 reference

Peter Jenner

1

1 reference

6 August 2017

publication date

1 January 2003

1 reference

6 August 2017

number of pages

7

1 reference

Parkinsonism and Related Disorders

inferred from page(s)

published in

1 reference

6 August 2017

volume

9

1 reference

6 August 2017

issue

3

1 reference

6 August 2017

page(s)

131-137

1 reference

Chronic parkinsonism secondary to intravenous injection of meperidine analogues

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

6-hydroxy-dopamine induced degeneration of central monoamine neurons

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

Neurochemical and behavioural features induced by chronic low dose treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset: implications for Parkinson's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

MPTP-induced parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

The effect of fetal mesencephalon implants on primate MPTP-induced parkinsonism. Histochemical and behavioral studies.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

Alleviation of experimental hemiparkinsonism by high-frequency stimulation of the subthalamic nucleus in primates: a comparison with L-Dopa treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

Subthalamotomy improves MPTP-induced parkinsonism in monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

The selective toxicity of 1-methyl-4-phenylpyridinium to dopaminergic neurons: the role of mitochondrial complex I and reactive oxygen species revisited.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

Assessment of motor behavior using a video system and a clinical rating scale in parkinsonian monkeys lesioned by MPTP.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

Comparison of eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the Macaque monkey

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

Characterisation of dyskinesias induced by L-dopa in MPTP-treated squirrel monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

Drug-induced dyskinesia in primates rendered hemiparkinsonian by intracarotid administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

Induction of chorea and dystonia in parkinsonian primates

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

Long-term treatment of Parkinson's disease with bromocriptine

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

Selective D2 receptor stimulation induces dyskinesia in parkinsonian monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

Levodopa motor complications in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

Continuous dopamine-receptor stimulation in early Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

Continuous dopamine-receptor stimulation in advanced Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

Cabergoline, a long-acting dopamine D2-like receptor agonist, produces a sustained antiparkinsonian effect with transient dyskinesias in parkinsonian drug-naive primates.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus).

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. The 053 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

Ropinirole in the treatment of early Parkinson's disease: A 6-month interim report of a 5-year levodopa-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

Levodopa in the treatment of Parkinson's disease: a consensus meeting

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

Entacapone enhances levodopa-induced reversal of motor disability in MPTP-treated common marmosets

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

Effect of pulsatile administration of levodopa on dyskinesia induction in drug‐naïve MPTP‐treated common marmosets: Effect of dose, frequency of administration, and brain exposure

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

Experimental models of Parkinson's disease: from the static to the dynamic

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

Differential vulnerability of primate caudate-putamen and striosome-matrix dopamine systems to the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

The neurotoxin MPTP does not reproduce in the rhesus monkey the interregional pattern of striatal dopamine loss typical of human idiopathic Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

Symptomatic and asymptomatic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates: biochemical changes in striatal regions

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900115-3

7 January 2021

10.1016/S1353-8020(02)00115-3

Identifiers

DOI

1 reference

6 August 2017

1 reference